© Copyright 2026, All Rights Reserved
Rationally designed Targeted Glue® technology for next-gen protein degradation therapies
Develop therapies for diseases with high unmet need; Advance treatments for intractable conditions; Target pathogenic proteins in specific tissues; Design degraders with improved performance over traditional PROTACs; Expand therapeutic scope beyond current TPD limitations
Founded by Advent Life Sciences; Built on science from Professor Alessio Ciulli's lab at University of Dundee; HQ in Cambridge, UK biopharma hub; Employee count 51-200; Founded in 2017